Table IV.
Correlations between clinical parameters and the methylation of p33ING1b promoter in fecal DNA from colorectal cancer patients.
| p33ING1b methylation, n (%) | |||||
|---|---|---|---|---|---|
|
|
|||||
| Group | Patients, n | Methylated | Unmethylated | χ2 | P-value |
| Gender | 0.176 | 0.674 | |||
| Male | 37 | 28 (75.68) | 9 (24.32) | ||
| Female | 24 | 17 (70.83) | 7 (29.17) | ||
| Age, years | 0.434 | 0.510 | |||
| ≤58 | 30 | 21 (70.00) | 9 (30.00) | ||
| >58 | 31 | 24 (77.42) | 7 (22.58) | ||
| Tumor location | 79.31 | 0.349 | |||
| Colon | 29 | 23 (79.31) | 6 (20.69) | ||
| Rectum | 32 | 22 (68.75) | 10 (31.25) | ||
| Pathological differentiation | 1.490 | 0.222 | |||
| High or middle | 38 | 26 (68.42) | 12 (31.58) | ||
| Low | 23 | 19 (82.61) | 14 (17.39) | ||
| Lymph node metastasis | 0.218 | 0.640 | |||
| Presence | 22 | 17 (77.27) | 5 (22.73) | ||
| Absence | 39 | 28 (71.79) | 11 (28.21) | ||
| Distant metastasis | 0.085 | 0.771 | |||
| Presence | 9 | 9 (81.82) | 2 (18.18) | ||
| Absence | 52 | 36 (72.00) | 14 (28.00) | ||
| Dukes’ stage | 0.617 | 0.432 | |||
| A/B | 33 | 23 (69.70) | 10 (30.30) | ||
| C/D | 28 | 22 (78.57) | 6 (21.43) | ||
p33ING1b, p33 inhibitor of growth 1b.